Our results also confirmed that γδ+ T-cells in IFN-α treated CML patients expressed corresponding cytokine receptors (CCR2/MCP-1 and CCR3/eotaxin). This evidence concerns the gene CCR2 and chronic myelogenous leukemia, BCR-ABL1 positive.